Attr Cm clinical trials

Explore recruiting attr cm clinical trials.

Recruiting attr cm studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Attr Cm trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac amyloidosis

France

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study to Evaluate the Efficacy and Safety of Amyloid Depleter ALXN2220 in Adult Participants with Transthyretin Amyloid Cardiomyopathy (ATTR-CM)

Spain, Netherlands, Poland, Italy, Belgium, France +8 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Efficacy and safety of NNC6019-0001 at two dose levels in participants with transthyretin amyloid cardiomyopathy (ATTR CM).

Portugal, Netherlands, Germany, Spain, Czechia, Italy +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

(23026) A prospective, single-arm, Phase 4 study to evaluate the course of serum transthyretin (TTR) level with acoramidis in adult patients with variant or wild-type transthyretin amyloidosis with cardiomyopathy (ATTR-CM) previously treated with tafamidis.

Austria, Germany, Italy, Belgium

Therapeutic use (Phase IV) EU CTIS Study details

Open-label extension study of long-term safety and efficacy of NNC6019-0001 in participants with transthyretin amyloid cardiomyopathy (ATTR CM)

Italy, Czechia, Netherlands, France, Spain, Germany +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled Study of Acoramidis for Transthyretin Amyloidosis Prevention in the Young (ACT-EARLY Trial)

Bulgaria, Portugal, Germany, Italy, Netherlands, France +6 more

Therapeutic confirmatory (Phase III) EU CTIS Study details

Attr Cm trials by city

Attr Cm in Toronto Attr Cm in Vancouver Attr Cm in Montreal Attr Cm in Calgary Attr Cm in Edmonton Attr Cm in Ottawa Attr Cm in Winnipeg Attr Cm in Quebec City Attr Cm in Hamilton Attr Cm in Kitchener Attr Cm in London Attr Cm in Halifax Attr Cm in New York Attr Cm in Los Angeles Attr Cm in Chicago Attr Cm in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease